title: At last, a truly selective EP₂ receptor antagonist.
abstract: Ever since the discovery of prostaglandin E(2)(PGE(2)), this lipid mediator has been the focus of intense research. The diverse biological effects of PGE(2) are due, at least in part, to the existence of four distinct receptors (EP(1-4)). This can complicate the analysis of the biological effects produced by PGE2. While there are currently selective pharmacological tools to explore the roles of the EP(1,3,4) receptors in cellular and tissue responses, analysis of EP(2) receptor-induced responses has been hampered by the lack of a selective EP(2) receptor antagonist. The recent publication in this journal by af Forselles et al. suggests that such a tool compound is now available. In their manuscript, the authors describe a series of experiments that show PF-04418948 to be a potent and selective EP(2) receptor antagonist. The discovery of this tool compound will interest many scientists and through collaborations with Pfizer they may have access to PF-04418948 to facilitate further investigation of the biology of this fascinating lipid mediator.
authors: Respiratory Pharmacology, Pharmacology & Toxicology Section, Imperial College London, Faculty of Medicine, National Heart and Lung Institute, London, UK. m.birrell@imperial.ac.uk
authors: Mark A
authors: MA
authors: Birrell
authors: Anthony T
authors: AT
authors: Nials
references: Arterioscler Thromb Vasc Biol. 2011 May;31(5):1049-58
references: 21311040
references: Am J Physiol Gastrointest Liver Physiol. 2010 Nov;299(5):G1078-86
references: 20798358
references: Am J Respir Crit Care Med. 2009 Nov 15;180(10):923-8
references: 19729667
references: Br J Pharmacol. 2011 Jul;163(6):1237-49
references: 21426319
references: Thorax. 2011 Dec;66(12):1029-35
references: 21606476
references: Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12233-8
references: 20566843
references: J Mol Med (Berl). 2009 Oct;87(10):1015-22
references: 19609495
references: Physiol Rev. 1999 Oct;79(4):1193-226
references: 10508233
references: Br J Pharmacol. 2011 Dec;164(7):1847-56
references: 21595651